Rapport Therapeutics, Inc. RAPP RAP219Program External Expenses — Research And Development Expense

Other product segments

Similar metrics at other companies

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

AMLXOther Programs — Research And Development Expense Excluding Acquired In Process Cost

$7.98M+111%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

TYRAOther Development Programs — Research And Development Expense

$849K+65.2%

ANABExternal Expenses — Research And Development Expense Reversal Excluding Acquired In Process Cost

$18.66M-32.4%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

Questions, answered.

What is Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense?

Rapport Therapeutics, Inc. (RAPP) reported rap219program external expenses — research and development expense of $15.82M in Q1 2026.

How has Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense changed year-over-year?

Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense increased by 98.7% year-over-year, from $7.96M to $15.82M.

What is the long-term trend for Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense?

Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense has grown at a 100.8% compound annual growth rate (CAGR), from $10.2M to $41.14M.

What does rap219program external expenses — research and development expense mean?

This metric represents the direct external costs incurred for the research and development activities specifically associated with the RAP219 clinical program. It captures third-party expenditures such as contract research organization fees, clinical trial site costs, and manufacturing expenses dedicated to advancing this specific therapeutic candidate. Monitoring this figure allows investors to track the capital intensity and development velocity of the company's primary pipeline assets.